Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: gemcitabine hydrochloride, troxacitabine, gemcitabine +4 | 1.00 |
| trials ClinicalTrials.gov | 17 Parkinson's trials, 3 stopped | 0.86 |
| literature PubMed | 1 Parkinson's papers of 62 | 0.91 |
| pathways Reactome | 9 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 16402
Sealed predictions
- PRIM2 in dopamine neurons, braak+0.51 (p 0.160) → +0.58 (p 0.102)receipt 16410
Swarm cases
receipt 16410: PRIM2 in dopamine neurons, braak
- power
- full sample +0.61 (p 0.0075, n 18), 95% CI +0.20 to +0.84. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.64 (p 0.0044, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.62 (p 0.0064, n 18). not the mix.
- skeptic
- leave-one-out range +0.55 to +0.71, sign flips 0; without severely affected donors +0.61 (p 0.0075, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PRIM2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts